48 results on '"Janus Kinase"'
Search Results
2. Patients with High Baseline Neutrophil-to-Lymphocyte Ratio Exhibit Better Response to Filgotinib as Treatment for Rheumatoid Arthritis
3. Baricitinib Improvement Across Regions in Atopic Dermatitis Patients with Baseline Body Surface Area up to 40% and Severe Itch
4. Honokiol Prevents Intestinal Barrier Dysfunction in Mice with Severe Acute Pancreatitis and Inhibits JAK/STAT1 Pathway and Acetylation of HMGB1
5. Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study
6. Protocol for a systematic review and meta-analysis on Janus kinase inhibitors in the management of vitiligo
7. Deciphering the molecular choreography of Janus kinase 2 inhibition via Gaussian accelerated molecular dynamics simulations: a dynamic odyssey
8. Management of Patients with Early Myelofibrosis: A Discussion of Best Practices
9. Tofacitinib use in ulcerative colitis: An expert consensus for day-to-day clinical practice
10. Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
11. Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis
12. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
13. Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices
14. How I manage anemia related to myelofibrosis and its treatment regimens
15. A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring
16. Molecular Pathogenesis of Myeloproliferative Neoplasms
17. Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis
18. Tofacitinib combined with leflunomide for treatment of psoriatic arthritis with IgA nephropathy: a case report with literature review
19. The Janus kinase inhibitor (baricitinib) suppresses the rheumatoid arthritis active marker gliostatin/thymidine phosphorylase in human fibroblast-like synoviocytes
20. Mortality outcomes and survival patterns of patients with myeloproliferative neoplasms in Malaysia
21. Pan-cancer analysis identifies ESM1 as a novel oncogene for esophageal cancer
22. Inhibition of JAK-STAT Signaling by Baricitinib Reduces Interferon-γ-Induced CXCL10 Production in Human Salivary Gland Ductal Cells
23. Interleukin-17A up-regulates thymic stromal lymphopoietin production by nasal fibroblasts from patients with allergic rhinitis
24. Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions
25. A small-molecule screen reveals novel modulators of MeCP2 and X-chromosome inactivation maintenance
26. Development of piperidinyl dipyrrrolopyridine-based dual inhibitors of Janus kinase and Bruton’s tyrosine kinase: a potential therapeutic probability to deal with rheumatoid arthritis
27. Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
28. Defective JAK-STAT Pathway Signaling Contributes to Autoimmune Diseases
29. The multi-site docking protein Grb2-associated binder 1 (Gab1) enhances interleukin-6-induced MAPK-pathway activation in an SHP2-, Grb2-, and time-dependent manner
30. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations
31. Inhibitory effect of JAK inhibitor on mechanical stress-induced protease expression by human articular chondrocytes
32. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group
33. Tofacitinib inhibits granulocyte–macrophage colony-stimulating factor-induced NLRP3 inflammasome activation in human neutrophils
34. Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
35. Recovery of nail dystrophy potential new therapeutic indication of tofacitinib
36. Regulation of Voltage-Gated K+ Channel Kv1.5 by the Janus Kinase JAK3
37. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo
38. Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance
39. Effect of Janus Kinase 3 on the Peptide Transporters PEPT1 and PEPT2
40. Progastrin Peptides Increase the Risk of Developing Colonic Tumors: Impact on Colonic Stem Cells
41. Modified high-density lipoprotein modulates aldosterone release through scavenger receptors via extra cellular signal-regulated kinase and Janus kinase-dependent pathways
42. Very-low-density lipoprotein mediates transcriptional regulation of aldosterone synthase in human adrenocortical cells through multiple signaling pathways
43. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients
44. Artocarpus altilis CG-901 alters critical nodes in the JH1-kinase domain of Janus kinase 2 affecting upstream JAK/STAT3 signaling
45. Opposing roles for Drosophila JAK/STAT signalling during cellular proliferation
46. Mesenteric venous thrombosis secondary to an unsuspected JAK2 V617F-positive myeloproliferative disorder
47. Leptin activates PI-3 kinase in C2C12 myotubes via janus kinase-2 (JAK-2) and insulin receptor substrate-2 (IRS-2) dependent pathways
48. Regulation of macrophage-mediated chronic inflammation by JAK inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.